Pompe Disease - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Pompe Disease Market Outlook

Thelansis's "Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pompe Disease Overview

Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) - encoded by the GAA gene - resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical spectrum ranging from classic infantile-onset Pompe disease - presenting within months of birth with hypertrophic cardiomyopathy, profound hypotonia, respiratory failure, and rapidly fatal course without treatment - to late-onset disease manifesting with progressive proximal myopathy, respiratory insufficiency, and preserved cardiac function across childhood or adulthood. Diagnosis integrates dried blood spot GAA enzyme activity assay as the primary screening tool, confirmed by GAA gene sequencing and muscle biopsy demonstrating lysosomal glycogen accumulation. Enzyme replacement therapy - alglucosidase alfa - established the therapeutic foundation, while cipaglucosidase alfa combined with the pharmacological chaperone miglustat represents a significant advancement, demonstrating superior glycogen clearance and clinically meaningful functional improvements over standard ERT. Respiratory surveillance with pulmonary function testing, nocturnal oximetry, and ventilatory support - including non-invasive ventilation - are critical management pillars. Physiotherapy and multidisciplinary rehabilitation optimise functional capacity. Prognosis has improved substantially with early treatment initiation, particularly through newborn screening programmes; patient-centred care, genetic counselling, and psychosocial support are integral to long-term disease management.

Key Highlights

• In Germany, Pompe Disease prevalent cases are projected to increase from 1,401 patients in 2025 to 1,510 patients in 2035, reflecting gradual improvement in diagnosis and patient survival.
• Increasing awareness, improved genetic testing, and expansion of rare disease screening programs are supporting earlier diagnosis across Germany.
• Current treatment landscape is primarily dominated by enzyme replacement therapies (ERTs), with growing focus on next-generation therapies offering improved efficacy and tissue penetration.
• Persistent unmet need exists for durable treatment options capable of addressing long-term muscle degeneration, respiratory decline, and variable response to existing ERTs.
• Emerging pipeline therapies, including gene therapies and enhanced GAA replacement approaches, are expected to reshape the future treatment paradigm.

Market Overview

• The Germany Pompe Disease market is projected to grow from USD 74 million in 2025 to USD 185 million by 2035, indicating substantial market expansion over the forecast period.
• Market growth is driven by:
• Increasing diagnosis and treatment rates among late-onset Pompe Disease patients
• Rising adoption of advanced and premium-priced enzyme replacement therapies
• Improved patient survival and long-term disease management
• Future market expansion will largely depend on innovations that improve long-term functional outcomes, reduce treatment burden, and address progressive muscle deterioration.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genzyme, a Sanofi Company
• Shionogi
• AskBio Inc.
• Amicus Therapeutics
• GeneCradle Inc.
• Astellas Gene Therapies